SINOVAC Announces Decision to Declare Cash Dividend




SINOVAC Announces Decision to Declare Cash Dividend

BEIJING–(BUSINESS WIRE)–Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Company’s board of directors (the “Board”) has decided to declare a special cash dividend of US$55.00 per common share (the “Dividend”). The Board expects to fund the Dividend from available cash resources of the Company and its subsidiaries, including prior distributions from Sinovac Life Sciences Co., Ltd. and other operating subsidiaries of the Company to Sinovac Biotech (Hong Kong) Limited. The Dividend is intended to provide SINOVAC shareholders with their appropriate share of these prior distributions from the Company’s subsidiaries. Going forward, the Board also intends for SINOVAC shareholders to receive pro-rata distributions in due course with any distributions made to stakeholders of operating subsidiaries. The Board will work with the Company’s management to update the holders of its common shares on the expected record and payment dates for the Dividend as soon as practicable.

As previously disclosed, a recent court order from the Privy Council (the “Order”) ruled, among other things, that the slate of nominees proposed by a group of shareholders at the Company’s Annual General Meeting held on February 6, 2018, was rightfully elected to the board of directors of SINOVAC at that meeting and has been the legitimate board of directors of the Company since then. To implement the Order and fulfill their fiduciary duties to the Company, the current members of the Board are assessing certain corporate actions taken by the former board of directors of the Company after they ceded office. One such corporate action being assessed is the issuance of the 11,800,000 common shares purportedly issued pursuant to a certain securities purchase agreement with Vivo Capital, LLC and Prime Success, L.P. in July 2018 (the “2018 PIPE Shares”) approved by the former board of directors, which was determined by the Order as lacking authority to approve such a transaction. Following the determination of the record and payment dates for the Dividend, an amount equal to the aggregate amount of cash that would be payable under the Dividend in respect of the 2018 PIPE Shares, will, prior to the payment date, be set aside and retained by the Company pending final resolution of any issues with respect to the 2018 PIPE Shares based on the Board’s assessment in accordance with the Order and under the laws of Antigua and Barbuda.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc.

The COVID-19 vaccine, CoronaVac^®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive^®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive^®, is an innovative vaccine under “Category 1 Preventative Biological Products” and commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1^®, which has supplied the Chinese government’s vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu^®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

For more information, please visit the Company’s website at www.sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions and include, without limitation, the statements regarding the Company’s proposed special cash dividend and future distributions. Such statements are based upon the Company’s current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from those in the forward-looking statements, including without limitation risks, uncertainties and factors related to the implementation, timing, amount and source of funds for the dividend and future distributions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Contacts

Sinovac Biotech Ltd.

Helen Yang

Tel: +86-10-8279 9779

Email: ir@sinovac.com

Lubrizol Amplifies India Commitment with Local Technology and Innovation Center




Lubrizol Amplifies India Commitment with Local Technology and Innovation Center

• New state-of-the-art facility in Maharashtra will enhance Innovation, R&D and application development for Lubrizol and its customers, serving both local-for-local and local-for-global needs

• Facility builds on the success of the company’s existing India footprint by co-locating its labs and technical capabilities to accelerate development

• New facility builds on Lubrizol’s commitment of $350 million in localized manufacturing and in-region investments over the last two years

MUMBAI, India–(BUSINESS WIRE)–To accelerate India-based innovation, Lubrizol announced it will open a state-of-the-art Technology and Innovation Center in Maharashtra. The first of its kind for the company globally, the facility is designed to progress breakthrough innovations, expand collaboration, and enhance speed to market for Lubrizol and the many customers and industries it serves both in the region and globally.

The center will empower collaboration across Lubrizol, co-locating lab capabilities and expanding on the success of existing in-region technology Centers of Excellence (COE). The site will also include a Customer Experience Center, allowing Lubrizol to co-develop solutions with customers and partners. The facility will feature advanced analytical capabilities to support research needs, including automation and digital tools, allowing teams to apply decision science to accelerate next-generation solutions.

“Lubrizol has been synonymous with innovation for nearly 100 years, and this new center represents a significant commitment to our innovation locally,” said Bhavana Bindra, Lubrizol’s Managing Director India, Middle East and Africa. “The Technology and Innovation Center represents a significant commitment to our journey in the region. By bringing together expertise across multiple Lubrizol businesses, this facility will be a cornerstone of collaboration, automation and technological advancement for our teams and all those we serve.”

“An innovation center in Maharashtra provides proximity to key stakeholders, fostering seamless collaboration and operational efficiencies. Through a highly collaborative working space, the center enables strategic research and development, leveraging the best of our legacy innovation and formulation processes with future-state technology to help us take our quality innovation one step further,” said Dr. Rahul Misra, Lubrizol’s Sr. Director of Technology, India, Middle East and Africa.

Rebecca Liebert, Lubrizol’s President and Chief Executive Officer, added, “The Technology and Innovation Center will serve as a model for future global centers, aligning with our strategy of establishing interconnected innovation centers worldwide. Our innovation teams in India have already enabled significant innovation in the many industries we serve, including earning the company global customer innovation awards. We expect this center to expand on those successes.”

Lubrizol’s commitment to local R&D and innovation has been an active part of Lubrizol’s decades-long legacy in India. As one example, Lubrizol introduced CPVC piping to the India market 25 years ago, enabling clean drinking water for thousands across the region. Today the region is a global leader in CPVC technology. Lubrizol’s India Bar Soap COE has helped improve the structural integrity and sustainability of bar soap, ensuring soaps last longer and create less waste, earning recognition from leading global brands. To support emerging regulatory changes and trends in transportation, the company also has a variety of in-region innovators focused on next-generation additive solutions.

Lubrizol’s Technology and Innovation Center announcement follows multiple Lubrizol investment announcements, with a more than $350 million USD commitment into India over the last 18 months. This includes bolstering Lubrizol’s manufacturing strength in the region with plans to construct the company’s second largest manufacturing facility globally to support the region’s growing transportation and industrial markets, as well as a collaboration to build the world’s largest CPVC resin plant.* The company also opened a Global Capability Center in Pune last year, doubled its capacity at its Dahej, Gujarat, manufacturing site and announced several other projects. The new Lubrizol Technology and Innovation Center will continue to expand Lubrizol’s network in India.

* World’s largest based on single-site capacity for CPVC resin

About Lubrizol

Lubrizol, a Berkshire Hathaway company, is a science-based company whose specialty chemistry delivers sustainable solutions to advance mobility, improve well-being and enhance modern life. Every day, the innovators of Lubrizol strive to create extraordinary value for customers at the intersection of science, market needs and business success, driving discovery and creating breakthrough solutions that enhance life and make the world work better. Founded in 1928, Lubrizol has global reach and local presence, with more than 100 manufacturing facilities, sales and technical offices and more than 7,000 employees around the world. For more information, visit www.Lubrizol.com.

Contacts

Media Contact:

Pooja Shetty | pooja.shetty@lubrizol.com
IMEA Marketing and Communication Lead

The Lubrizol Corporation

Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims




Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims

Company has prevailed in 16 of 17 ovarian cases tried in the last 11 years

Company will reverse approximately $7 billion from amounts previously reserved for the bankruptcy resolution

NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Today, the U.S. Bankruptcy Court for the Southern District of Texas denied the request by Johnson & Johnson (NYSE: JNJ) (the “Company”) subsidiary Red River Talc LLC (“Red River”) to confirm its proposed prepackaged bankruptcy plan—notwithstanding that it offered one of the largest settlements ever proposed in a mass tort bankruptcy and was supported by the overwhelming majority of claimants.

Rather than pursue a protracted appeal, the Company will return to the tort system to litigate and defeat these meritless talc claims. The disclosures made under oath in the Red River bankruptcy affirmed that the talc litigation is a plaintiff-lawyer driven fake tort, premised on junk science and fueled by third party litigation financing including from foreign sovereign wealth funds. Consequently, the Company has no intent to settle or pay plaintiff lawyers on such meritless claims. Accordingly, the Company will reverse approximately $7 billion of the previous reserve.

“The Court has unfortunately allowed a couple of law firms with financially conflicted motives, who have conceded they have not recovered a dime for their clients in a decade of litigation, to defeat the overwhelming desire of claimants. As we have repeatedly stated, in the absence of plan confirmation, we will vigorously present our case in the tort system, starting with the adjudication of the motions pending in the Multi-District Litigation to exclude plaintiffs’ experts and to disqualify the lead counsel for its unethical breaches. In view of the learnings from the bankruptcy case, we are more confident than ever in our position in the tort system,” said Erik Haas, Worldwide Vice President of Litigation, Johnson & Johnson. “We prevailed in 16 of 17 ovarian cases tried in the last 11 years and will devote our efforts to defeating these fake claims.”

The Company has already made great strides in resolving its talc litigation by settling 95% of filed mesothelioma lawsuits, concluded all State consumer protection claims, as well as all talc-supplier disputes.

“Today’s decision highlights the broken tort system in the United States. The Company reiterates that none of the talc-related claims against it have merit and attempts to resolve this litigation were aimed at moving past this issue,” said Mr. Haas. “The decision to litigate every filed case is based on the simple fact that this is a fake claim created by greedy plaintiff lawyers looking for another deep pocket to sue and fueled by litigation-financed attorney advertising.”

To learn more about our position and the science supporting the safety of talc, visit www.FactsAboutTalc.com.

Investor Conference Call

Johnson & Johnson will conduct a conference call with investors to discuss the announcement tomorrow, April 1, at 8:00 a.m. ET. You can join via:

Participant Dial-In: 877-869-3847 (U.S.) / 201-689-8261 (International)

or

Webcast: https://event.webcasts.com/starthere.jsp?ei=1714307&tp_key=3814389bae
A replay will be available approximately two hours after the live webcast by visiting www.investor.jnj.com

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the dismissal of the prepackaged Chapter 11 bankruptcy plan. The reader is cautioned not to rely on these forward-looking statements. The information contained in this press release is for informational purposes only and should not be construed as a commitment by the Company to engage in any specific strategy or course of action. The Company cannot predict the timing, ultimate outcome or financial impact of this matter, or any other ongoing or future litigation. The forward-looking statements in this press release are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of LLT Management LLC, Red River Talc LLC and/or Johnson & Johnson. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. None of LLT Management LLC, Red River Talc LLC nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments. The Company expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Contacts

Media contact:
media-relations@its.jnj.com

Investor contact:

investor-relations@its.jnj.com

Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets




Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets

COLUMBUS, Ohio–(BUSINESS WIRE)–Navidea Biopharmaceuticals, Inc. (“Navidea” or the “Company”) today announced that its Board of Directors has elected to extend the Company’s Section 382 Rights Agreement (the “Section 382 Rights Plan”). Originally adopted on April 7, 2022, and set to expire on April 6, 2025, the plan has now been extended to April 7, 2027.

The Section 382 Rights Plan is designed to safeguard Navidea’s ability to utilize its net operating loss carryforwards (“NOLs”) and other tax assets. As of December 31, 2024, Navidea had approximately $170 million in U.S. federal NOLs and approximately $9 million in R&D tax credits that may be used to offset future taxable income. However, these valuable tax attributes could be significantly limited if the Company experiences an “ownership change” as defined by Section 382 of the Internal Revenue Code. Generally, an ownership change occurs if the collective ownership of Navidea’s stock by its “5-percent shareholders” increases by more than 50 percentage points over a rolling three-year period.

To help prevent such an event, the Section 382 Rights Plan discourages any individual or group from acquiring beneficial ownership of 4.99% or more of Navidea’s outstanding common stock. Under the plan, when originally adopted, the Board declared a dividend of one preferred share purchase right for each share of Navidea common stock outstanding as of the close of business on April 12, 2022. The rights will become exercisable only if a person or group acquires 4.99% or more of Navidea’s common stock.

If the rights are triggered, all shareholders—except for the acquiring party—will be entitled to purchase shares at a 50% discount or, alternatively, Navidea may exchange each right for five shares of common stock. The Board retains the authority to grant exemptions at its discretion.

Craig Dais, Navidea’s Chief Financial Officer, commented, “Extending the Section 382 Rights Plan ensures we continue to protect our significant NOLs, a key financial asset for the Company’s future.”

About Navidea

Navidea Biopharmaceuticals, Inc. (OTC: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, visit www.navidea.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review and consider the disclosures found in our SEC filings, which are available at http://www.sec.gov or at http://ir.navidea.com.

Investors are urged to consider statements that include the words “will,” “may,” “could,” “should,” “plan,” “continue,” “designed,” “goal,” “forecast,” “future,” “believe,” “intend,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.

You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward- looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.

Contacts

Investor Relations Contact
Navidea Biopharmaceuticals, Inc.

Craig A. Dais, Chief Financial Officer

cdais@navidea.com
(614)-822-2322

Ideagen shines in G2 Spring 2025 Reports with 82 badges and 31 top rankings




Ideagen shines in G2 Spring 2025 Reports with 82 badges and 31 top rankings

NOTTINGHAM, England–(BUSINESS WIRE)–#Australia–Global software company, Ideagen, is celebrating success in the G2 Spring 2025 Reports, earning 82 prestigious badges and 31 number one rankings this season – all thanks to the valued feedback from customers.

This milestone represents the highest number of G2 badge wins for Ideagen to date, more than doubling its achievements from the same period last year. Most importantly, this recognition reinforces the company’s position as a trusted partner for customers who rely on its solutions every day.

Among this season’s wins are 45 ‘Leader’ badges, in addition to number one ranking across 31 reports in the following categories:

• Enterprise Risk Management (ERM)
• Environmental, Quality and Safety Management
• Inspection Management
• Medical QMS
• Occupational Health and Safety (OHS)
• Pharma and Biotech
• Quality Management (QMS)
• Regulatory Change Management

Ideagen also achieved number one rankings in Regional Grid® Reports for Asia Pacific, Europe, EMEA and United Kingdom.

Two of this quarter’s standout highlights include Ideagen Quality Control, which achieved 15 number one rankings out of 20 badges and Ideagen Plant Assessor which was ranked number one in five reports out of eight. The machinery safety solution earned three ‘Leader’ awards along with ‘Best Relationship’, ‘Fastest Implementation’, ‘Best Est. ROI’, ‘Most Implementable’ and ‘Best Results’.

One G2 user said: “Love Ideagen Plant Assessor … It ultimately helps reduce downtime, minimize risks, and ensure compliance — all of which can result in significant cost savings and improved operational efficiency.”

“Ensuring people are protected in their work environments is critical,” said John Molamphy, Chief Technology Officer at Ideagen. “We’re here to support businesses build their resilience, be compliant, protect their teams and improve operational efficiency. The positive feedback from our customers this past quarter reflects their trust in Ideagen to deliver on these priorities.

“We want to thank everyone who took the time to share their reviews. This recognition underscores our commitment to providing clarity and confidence to regulated industries, and we remain focused on delivering innovative solutions that continue to delight our customers around the world.”

G2 is the go-to platform for over 100 million software buyers annually, leveraging insights from more than 2.9 million verified user reviews. Its quarterly reports provide real-time ratings of products and solutions across various criteria. Based on this data, G2 awards badges to the highest-performing companies, representing a mark of excellence and quality that businesses and professionals can use as a benchmark for purchasing decisions.

Discover the highlights of Ideagen’s G2 Spring 2025 achievements:

Ideagen Audit Analytics

• Seven total badge wins in Financial Research, including recognition as a High Performer in the Enterprise Grid® Report and Easiest to Use in the Usability Index
• Leader in both the Grid® Report and Momentum Grid® Report

Ideagen CompliSpace

• Two Leader badges in Regulatory Change Management, in both the Mid-Market Grid® Report and Grid® Report
• Leader in the Asia Pacific Regional Grid® Report for Regulatory Change Management and ranked #1

Ideagen EHS

• Three Leader badges in Environmental Health and Safety across the Grid® Report, Momentum Grid® Report and Mid-Market Grid® Report
• Leader in the EMEA Regional Grid® Report for Inspection Management
• Leader in the Momentum Grid® Report for Occupational Health and Safety (OHS)

Ideagen Huddle

• Seven High Performer badges in Cloud Content Collaboration including for the Grid® Report, Mid-Market Grid® Report and Europe Regional Grid® Report
• Fastest Implementation in the Enterprise Implementation Index for Cloud Content Collaboration
• Best Est. ROI in the Enterprise Results Index for Cloud Content Collaboration

Ideagen Mail Manager

• Highest User Adoption badge in the Small-Business Implementation Index for Email Management

Ideagen Op Central

• Three Leader badges in Corporate Learning Management Systems across the Australia Regional Grid® Report, ANZ Regional Grid® Report and Asia Pacific Regional Grid® Report
• High Performer in the Grid® Report for Corporate Learning Management Systems

Ideagen Plant Assessor

• Nine badge wins in Occupational Health and Safety (OHS) and five #1 rankings. This includes two Leader badges in the Mid-Market Grid® Report and Grid® Report, along with securing Most Implementable in the Implementation Index and Best Results in the Results Index
• Leader in the Grid® Report for Environmental, Quality and Safety Management

Ideagen PleaseReview

• Leader and ranked #1 in the Grid® Report for Pharma and Biotech
• Leader in the Momentum Grid® Report for Document Creation

Ideagen Quality Control

• 17 wins in Inspection Management, including five Leader badges across the Grid® Report, EMEA Regional Grid® Report, Small-Business Grid® Report, Mid-Market Grid® Report and Momentum Grid® Report. In addition, recognized for Best Usability in the Usability Index, Best Results in the Results Index and Most Implementable in the Implementation Index
• Three badges in Environmental, Quality and Safety Management, including being named Leader in the Grid® Report

Ideagen Quality Management

• Nine Leader badges in Quality Management (QMS) including for the Grid® Report, Small-Business Grid® Report and Mid-Market Grid® Report
• Ranked #1 in the United Kingdom Regional Grid® Report, Mid-Market Europe Regional Grid® Report, Mid-Market EMEA Regional Grid® Report, EMEA Regional Grid® Report, Momentum Grid® Report and Europe Regional Grid® Report
• Leader in both the Europe Regional Grid® Report for Medical QMS and EMEA Regional Grid® Report for Medical QMS, ranking #1 across both
• Leader in the Grid® Report for Environmental, Quality and Safety Management

Ideagen Risk Management

• Leader in the EMEA Regional Grid® Report for Enterprise Risk Management (ERM)
• Leader in the Europe Regional Grid® Report for Enterprise Risk Management (ERM) and ranked #1

Ideagen WorkRite

• Seven Leader badges in Ethics and Compliance Learning, including the EMEA Regional Grid® Report and Enterprise Grid® Report

Contacts

Rebecca Watson

Head of Marketing Communications

rebecca.watson@ideagen.com

Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection




Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection

• First multiplexed solution introduced with the next-generation Cyto-Mine Chroma platform for more efficient biotherapeutic development
• Utilizes advanced picodroplet microfluidics technology to integrate analysis of antibody productivity and cell viability of monoclonal antibody producing cells

CAMBRIDGE, England–(BUSINESS WIRE)–Sphere Bio, a leading provider of innovative picodroplet-based microfluidics solutions for functional single-cell analysis and isolation, today announced the launch of the Cyto-Cellect^® Human IgG Kappa and Viability Assay Kit, the first multiplexed assay developed specifically for the Company’s new Cyto-Mine^® Chroma platform.¹

The Cyto-Mine Chroma platform uses fluorescence-based assays in picodroplets to select single cells based on secreted, surface, and/or intracellular markers. Aided by the new multiplexing capability of the Chroma system, the Cyto-Cellect Human IgG Kappa and Viability Assay Kit represents a significant advancement enabling researchers to complete workflows faster and at lower cost, while simultaneously improving the quality and viability of cells (clones) that are selected.

By simultaneously detecting secreted antibodies and assessing a viability stain on the cell surface, this new assay enables high-throughput screening of viable, high-producing clones in a single automated workflow. Preliminary data indicate that approximately five percent of selected high-producing clones are apoptotic (dead or dying). Screening out these clones at an early stage reduces the risk of false positives and ensures only the highest producers are selected for downstream analysis or development.

Key features and benefits of Cyto-Cellect Human IgG Kappa and Viability Assay Kit combined with the capabilities of Cyto-Mine Chroma include:

• Advanced multiplexing capabilities to simultaneously analyse productivity and viability markers, ensuring optimal selection outcomes
• Streamlined workflows to reduce development timelines from months to hours
• Unprecedented throughput and significantly lower costs compared to other methods
• On-board monoclonality assurance

The launch represents a significant milestone in the development of Sphere Bio’s product portfolio, as part of the Company’s mission to deliver transformative solutions for cell line development that set new industry benchmarks for efficiency and reliability.

Dr. Xin Liu, Senior Product Manager for Assays and Applications, Sphere Bio, commented: “Our new assay kit is a game-changer for single-cell workflows. By integrating viability assessment with antibody detection, we can ensure that only the healthiest, most productive cells are selected, significantly improving the efficiency and outcomes of our customers’ research.”

Dr. Maryam Ahmadi, Director of Science, Sphere Bio, added: “The Cyto-Cellect Human IgG Kappa and Viability Assay Kit leverages the advanced capabilities of Cyto-Mine Chroma to deliver unparalleled precision in single-cell analysis. The new assay represents the first launch in our roadmap of multiplex assays compatible with Chroma, bringing advanced multiplexing capabilities to our customers through our expanding portfolio of cutting-edge tools and solutions to accelerate scientific discovery.”

To learn more about the Cyto-Cellect Human IgG Kappa and Viability Assay Kit, please visit https://spherebio.com/product/cyto-cellect-human-igg-kappa-viability-assay-kit/

1. Press release (27^th January 2025) Sphere Bio launches Cyto-Mine^® Chroma and announces Early Access Program

Contacts

For further information please contact:
Dr. Claire Cox

Sphere Bio Ltd.

Tel: +44 (0)7365 209 441

Email: claire.cox@spherebio.com

Zyme Communications

Lily Jeffery

Tel: +44 (0)7891 477 378

Email: lily.jeffery@zymecommunications.com

GE HealthCare Completes Acquisition of Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan




GE HealthCare Completes Acquisition of Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan

• GE HealthCare has completed its acquisition of Sumitomo Chemical’s 50% stake in Nihon Medi-Physics (NMP), giving it full ownership.
• As part of GE HealthCare, NMP, already a leading radiopharmaceutical company in Japan, is positioned to enhance patient access to next-generation radiopharmaceuticals that enable detection and diagnosis of disease
• Kevin O’Neill, President & CEO of GE HealthCare’s Pharmaceutical Diagnostics segment, will also become President of NMP.

CHICAGO–(BUSINESS WIRE)–GE HealthCare Technologies Inc. (GE HealthCare or the Company) (Nasdaq: GEHC) has completed its acquisition of the remaining 50% stake in Nihon Medi-Physics Co., Ltd (NMP), from Sumitomo Chemical, giving it full ownership. As part of GE HealthCare, NMP can further build on its expertise in developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures to detect and diagnose disease.

Kevin O’Neill, President & CEO of GE HealthCare’s Pharmaceutical Diagnostics (PDx) segment, who will also become President of NMP, said: “We are delighted to welcome Nihon Medi-Physics to GE HealthCare, increasing our existing footprint and offering in Japan, where our contrast media and medical devices are used every day to enable imaging procedures across the country. Japan is on a path to becoming a leader in the $7 billion molecular imaging global market¹ and a center of excellence for Asian markets. As part of GE HealthCare, NMP will play a key role in that journey, including bringing its deep expertise and scale to global innovators looking to bring next-generation radiopharmaceuticals to the Japan market and beyond.”

NMP’s product portfolio includes GE HealthCare radiopharmaceuticals used to enable molecular imaging across neurology, cardiology and oncology procedures. NMP, headquartered in Tokyo, was formed in 1973 and generated revenues of 28.2B JPY (~$183M) in 2023. GE HealthCare acquired Amersham plc in 2004, and subsequently held a 50% stake in NMP.

The Company expects this transaction to be neutral to Adjusted EPS² in year one and accretive thereafter.

GE HealthCare was advised by Solomon Partners Securities, LLC.

The intent to acquire the remaining 50% stake in NMP was announced in December 2024.

Forward-Looking Statements

This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the transaction, the expected results of the transaction, future market conditions, and the Company’s performance, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the Company may be unable to achieve the anticipated benefits of the transaction; operating costs and business disruptions (including, without limitation, difficulties in maintaining relationships with employees, customers, and suppliers) may be greater than expected; and the Company may assume unexpected risks and liabilities. Other factors that may cause such a difference also include those discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

¹ GE HealthCare estimated global end markets as of December 2023, and estimated market CAGR 2024–2028.

² Non-GAAP financial measure. See our earnings release dated February 13, 2025 for the definition of Adjusted EPS.

Contacts

Media contact
David Morris

Executive, Communications, Pharmaceutical Diagnostics

GE HealthCare

+44 7920591370

david.j.morris@gehealthcare.com

Sensorion Announces Webconference, in French, for its Retail Shareholders on April 7, 2025




Sensorion Announces Webconference, in French, for its Retail Shareholders on April 7, 2025

• Sensorion to host a webconference dedicated to its retail shareholders on April 7, 2025, in French, at 6.30pm CET (12.30pm ET)

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced it will host a webconference for its retail shareholders on April 7, 2025, following its Full-Year 2024 release. The webconference will be held in French.

Sensorion’s Chief Executive Officer, Nawal Ouzren, and management team, will host a webconference dedicated to its retail shareholders, in French, on April 7, 2025, at 6.30pm CET (12:30pm ET), to comment on the Company’s latest announcements and outlook.

Click here to join the meeting
Meeting ID: 338 799 647 078

Secret Code: Bi9wg2Py

You will also be able to join the webconference from Sensorion’s website.

A replay of the webconference will be available on the Company’s website.

About Sensorion

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.

It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.

Sensorion’s portfolio also comprises programs of a clinical-stage small molecule, SENS-401 (Arazasetron), for the treatment and prevention of hearing loss disorders. Sensorion’s small molecule progresses in a Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) for the preservation of residual hearing. Sensorion, with partner Cochlear Limited, completed in 2024 a Phase 2a study of SENS-401 for the residual hearing preservation in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022.

www.sensorion.com

Label: SENSORION

ISIN: FR0012596468

Mnemonic: ALSEN

Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2024 full year report published on March 14, 2025, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.

Contacts

Investor Relations
Noémie Djokovic, Investor Relations and Communication Associate

ir.contact@sensorion-pharma.com

Press Relations
Ulysse Communication

Bruno Arabian / 00 33(0)6 87 88 47 26

barabian@ulysse-communication.com
Nicolas Entz / 00 33 (0)6 33 67 31 54

nentz@ulysse-communication.com

Novotech Welcomes New Investment From GIC, Temasek, and Existing Investor TPG to Accelerate Global Growth




Novotech Welcomes New Investment From GIC, Temasek, and Existing Investor TPG to Accelerate Global Growth

SYDNEY–(BUSINESS WIRE)–#GIC–Novotech, a globally recognized full-service biotech specialist clinical research organization (CRO), announced today that affiliates of GIC and Temasek have signed binding agreements to acquire a significant stake in the company, with the additional capital earmarked to accelerate its global growth. Existing investor TPG will also reinvest through its TPG Asia fund.

Novotech, headquartered in Singapore with a global presence across more than 30 offices, is one of the world’s leading full-service clinical CROs, providing biotech and small- to mid-sized pharmaceutical companies with an accelerated path to market. Today, the company has a global footprint across the Asia-Pacific region, North America and Europe, and partnerships with more than 5,000 trial sites. Novotech has a leading position in the most innovative areas of clinical research such as cell and gene therapies, radiopharmaceuticals and mRNA trials.

The reinvestment by TPG Asia and investment from GIC and Temasek will allow Novotech to pursue further organic growth and transformative M&A opportunities. This is part of Novotech’s ambition to become the first truly global biotech-focused CRO.

Novotech Chief Executive Officer John Moller welcomed the new investment and said the company was uniquely positioned to continue its growth in the Asia Pacific region, where demand for clinical trials is forecasted to grow at 15% a year, in addition to focused expansion in the US and Europe.

“Novotech is already on its way to be a major global player in the CRO space, with 3,000 employees and experience across more than 6,000 clinical projects,” Dr. Moller said. “We are excited by the new support of GIC and Temasek, and the continued support of TPG, as we continue to scale the business while maintaining our high-quality standards.

We have a commanding presence in the Asia Pacific region – which is only growing in popularity for global trials as the trend towards outsourcing continues, particularly among biotechs – and have made significant gains in the US and Europe through acquisitions. This investment will ensure we can continue our record of winning a growing share of larger, multi-region trials, particularly ones with a center of gravity in Asia, and it will also enable us to pursue larger, transformation acquisitions as our industry inevitably consolidates.”

Joel Thickins, Co-Head of TPG Asia and Co-Managing Partner of TPG Capital Asia, said: “Novotech’s growth and performance has been outstanding over the years, and we are delighted to remain involved for the next stage of its global expansion. Since our investment in 2017, Novotech has grown from a 300-person organization operating predominantly in Australia and New Zealand and some parts of Asia, to now a 3,000-person organization with a global presence. TPG has a long history of partnering with management teams to deliver long-term value creation, and by re-investing through TPG Asia, we are excited to continue the journey with Novotech to build something that is truly unique.”

TPG Asia has a strong track record investing in healthcare across Asia-Pacific through its platform-building strategy and regional presence. Other select healthcare investments include iNova, Manipal Hospitals, One Healthcare Asia, Pathology Asia and United Family Healthcare.

Vincent Wong, Co-Head of Healthcare, TPG Capital Asia, added: “Delivering high-quality healthcare relies on building great companies achieved through long-term commitment, and this transaction follows TPG’s playbook of doubling down on winners while further demonstrating TPG’s thematic investment approach and deep expertise in healthcare. Together with our history of partnering with Novotech, and TPG’s deep healthcare ecosystem that has been further strengthened with the recent establishment of a regional leadership model for healthcare investments across TPG Asia, we are well positioned to support Novotech in its multi-decade success story.”

Choo Yong Cheen, Chief Investment Officer of Private Equity at GIC, commented: “Novotech’s proven track record of delivering high-quality outcomes for its biopharma customers has taken them beyond APAC to global markets. We are pleased to support Novotech alongside TPG with our long-term capital and global network in this next phase of growth. We look forward to working with the management team and our partners in driving sustained growth by investing in organic initiatives and M&A.”

Terms of the transaction were not disclosed.

About Novotech

Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results.

About TPG

TPG is a leading global alternative asset management firm, founded in San Francisco in 1992, with $246 billion of assets under management and investment and operational teams around the world. TPG invests across a broadly diversified set of strategies, including private equity, impact, credit, real estate, and market solutions, and our unique strategy is driven by collaboration, innovation, and inclusion. Our teams combine deep product and sector experience with broad capabilities and expertise to develop differentiated insights and add value for our fund investors, portfolio companies, management teams, and communities.

About GIC

GIC is a leading global investment firm established in 1981 to secure Singapore’s financial future. As the manager of Singapore’s foreign reserves, we take a long-term, disciplined approach to investing, and are uniquely positioned across a wide range of asset classes and active strategies globally. These include equities, fixed income, real estate, private equity, venture capital, and infrastructure. Our long-term approach, multi-asset capabilities, and global connectivity enable us to be an investor of choice. We seek to add meaningful value to our investments. Headquartered in Singapore, we have a global talent force of over 2,300 people in 11 key financial cities and have investments in over 40 countries.

For more information, please visit gic.com.sg or follow us on LinkedIn.

About Temasek

Temasek is a global investment company headquartered in Singapore, with a net portfolio value of S$389 billion (US$288b, €267b, £228b, RMB2.08t) as at 31 March 2024. Marking its unlisted assets to market would provide S$31 billion (US$23b, €21b, £18b, RMB166b) of value uplift and bring its mark to market net portfolio value to S$420 billion (US$311b, €289b, £247b, RMB2.25t).

Temasek’s Purpose “So Every Generation Prospers” guides it to make a difference for today’s and future generations.

Operating on commercial principles, Temasek seeks to deliver sustainable returns over the long term.

It has 13 offices in 9 countries around the world: Beijing, Hanoi, Mumbai, Shanghai, Shenzhen, and Singapore in Asia; and Brussels, London, Mexico City, New York, Paris, San Francisco, and Washington, DC outside Asia.

Contacts

For media inquiries:
Novotech
Toyna Chin

(USA) +1 415 364 8135

mediacontact@novotech-cro.com

TPG
Katelin Stevenson

TPGAsia@brunswickgroup.com

GIC
Mah Lay Choon

Head of Corporate Communications

+65 6889 6841

mahlaychoon@gic.com.sg

Toh Chuan Ting

Assistant Vice President, Corporate Communications

+65 8309 1038

tohchuanting@gic.com.sg

Temasek
Kelvin Ng

Director, Public Affairs

Tel: +65 6828 6939

kelvinng@temasek.com.sg

Rebekah Seow

Associate, Public Affairs

Tel: +65 6828 2500

rebekahseow@temasek.com.sg

Clinical Data Presented at ACC 2025 Shows Sensydia CPS™ Provides Accurate Assessment of Mean Pulmonary Artery Pressure Non-Invasively




Clinical Data Presented at ACC 2025 Shows Sensydia CPS™ Provides Accurate Assessment of Mean Pulmonary Artery Pressure Non-Invasively

— Non-invasive platform offers potential to transform heart failure care —

— CPS on display for physicians in Sensydia booth #8029 at the American College of Cardiology (ACC) Annual Scientific Session & Expo —

CHICAGO–(BUSINESS WIRE)–Sensydia, a clinical-stage non-invasive cardiac assessment company, announced today that University of Minnesota investigators presented positive clinical findings from a recent study evaluating the company’s AI-powered, non-invasive Cardiac Performance System (CPS™) in a poster presentation at the American College of Cardiology (ACC) 2025 Annual Scientific Session & Expo at the McCormick Place Convention Center in Chicago, IL.

Sensydia’s CPS uses heart sound analysis to enable earlier detection and more effective therapy guidance for patients suffering from heart failure and pulmonary hypertension. To obtain these measurements today, patients must undergo echocardiography and invasive right heart catheterization, which are resource intensive, restricted to medical facilities, and only provide snapshot data. In contrast, CPS measurements are fast, safe, may be repeated as frequently as needed, and can be performed essentially anywhere with minimal training.

Key findings

• The investigator-led study enrolled 50 patients undergoing routine right heart catheterization (RHC), with CPS successfully measuring mean pulmonary artery pressure (mPAP) in 40 subjects.
• CPS demonstrated its ability to identify patients with elevated mPAP (>35mmHg and >30mmHg) with strong diagnostic accuracy, achieving an AUC of 0.80 and 0.77, respectively.
• No complications or adverse reactions were reported, and patients tolerated the non-invasive CPS measurement well.

Significance of These Findings

For clinicians and healthcare providers, these findings underscore the potential of CPS to serve as a reliable alternative to invasive RHC. CPS could provide critical, real-time insights into hemodynamics in the clinic or the patient’s home, reducing the need for hospital-based monitoring while potentially improving patient outcomes and streamlining heart failure management.

“CPS offers a fast, non-invasive, and accurate tool to assess hemodynamics that could transform heart failure care,” said Tamas Alexy, MD, PhD of the University of Minnesota. “The ability to track changes in pulmonary artery pressure (PAP) with CPS can empower clinicians to make more informed and timely treatment decisions for patients with heart failure.”

ACC.25 attendees are invited to visit booth 8029 to explore CPS’s role in improving heart failure management and see a demonstration of CPS technology.

Please note: CPS is under development and not yet FDA-approved.

About Sensydia

Sensydia is developing the Cardiac Performance System (CPS™), a non-invasive platform that provides real-time measurements of critical cardiac function. CPS is designed to deliver rapid, safe, and accurate assessments to improve outcomes for patients with heart failure and pulmonary hypertension. The company received FDA 510(k) clearance for non-invasive measurement of ejection fraction using first-generation hardware in 2018. Learn more at sensydia.com.

Contacts

Media:
Kathryn Morris, BrightPoint

kathryn@brightpointny.com
914-204-6412